NEW PRODUCTS
SKIN REJUVENATION
HAIR RESTORATION
MEDI ESTHETIC
HEALTH SCIENCE
SIGNATURE BRANDS
WOUND HEALING <<
Background
Clinical Data
In Vivo Test
Commercial Markets
Product
MICRONEEDLE
M2 PEPTIDE
3D MINERALS
NOPAL JUICE
REINAHALEN
60 SECOND MIRACLES
AROSCA
SKINSHADE
HTA-7 (Reprotin)
MORE by ALION Lab <<
Brochure (46MB)
Download PDF Reader


ACT-1 & ACT-2: Miraculous multi-peptides with wound healing activity

There is increasing evidence that peptides associated with innate immunity and mucosal defense provide both protective and modulatory functions. Our aim is to isolate and adapt the modulatory functions from such peptides to provide stimulatory benefit to the wound healing process. From this work a lead candidate peptide has been identified that exhibits many of the attributes required within a wound healing therapeutic product profile. The peptide has demonstrated efficacy in both surgical and full-thickness-burn wound models. In addition, the peptide has been shown to be safe, with no observable dermal or systemic toxicity, as determined by a wide range of blood factor endpoints.


Introduction

ALION Lab presents peptides and formulations for novel products focusing on skin and wound physiology. The sole founder, inventor and scientific researcher is a molecular biologist who was trained in protein chemistry by two time Nobel prizewinner Linus Pauling. In the course of developing peptides aimed to modulate and restructure the skin, the inventor mastered the elements and processes of normal and abnormal skin physiology where she emphasized anti aging and the wound repair response.

Utilizing her expertise in peptide chemistry and abnormal wound healing events, she discovered and developed five novel peptides aimed to facilitate the body’s natural wound healing process. However, due to limited financial resources, only two of the peptides, ACT-1 and ACT-2, were tested in vitro, preclinical and in vivo studies. These studies found that both peptides accelerate and orchestrate wound healing by facilitating endothelial cell migration and proliferation in chronic and acute wounds.

Management believes that the ACT-1 and ACT-2 peptides are revolutionary in treating early and late stage chronic wounds such as diabetic foot ulcers and venous ulcers while decreasing the costs of therapy when compared to less effective traditional and non traditional therapeutic methods. ACT-1 and ACT-2 work independent of one another with similar efficacy to close chronic wounds and prevent recurrence. Management believes that ACT-1 and/or ACT-2 can be sold as an ethical drug and/or over the counter (OTC) and that neither formulation requires refrigeration, pre mixing or other processing steps prior to application.


Chronic Wound Management Provides a Growing Market Opportunity

Smith & Nephew estimated that the “Advanced Wound Management” market (which excludes traditional gauze dressings and the like) approached $1.8 billion worldwide in 2000. Frost&Sullivan estimates that the wound management product market in the U.S. alone will be $2.6 billion in 2002 and that the U.S. market usually accounts for half of the worldwide market. This growth is driven by: an aging population, a steady interest in employing higher technology, more clinically efficient and higher margin products are in the market, an increase in the number of people developing underlying diseases such as diabetes and venous insufficiency, and new treatments that are more cost effective than their conventional counterparts.


Biologically Active Molecules are Next Generation Technology for Chronic Wound Management

Biologically active molecules are believed to be the next generation of high technology wound healing products. Such biologically active products offer clients convenience, ease of use and cost savings when compared to other therapies such as Hyperbarbaric Oxygen Chambers and amputation. Importantly, molecules such as the ACT peptides analogs stimulate natural wound healing functions including Angiogenesis, enzyme production, cell migration, chemotaxis and cellular proliferation.

A unique feature of the ACT peptides is that they do not need to be refrigerated to maintain biological activity. Further support for the theory that biologically active molecules play a role in wound healing can be found in high quality peer reviewed primary research articles citing the presence or absence of specific molecules significantly influences the wound closure process.